Monoclonal Antibodies vs COVID-19: Eduardo Ojito-Magaz MS General Director, Molecular Immunology Center
2021; Volume: 23; Issue: 2 Linguagem: Inglês
10.37757/mr2021.v23.n2.17
ISSN1555-7960
AutoresTania L. Aguilar, Conner Gorry,
Tópico(s)Public Health and Environmental Issues
ResumoMEDICC Review: Cuba hopes to vaccinate its entire population this year with COVID-19 vaccines developed on the island.Can you tell us about CIM's role in producing the SOBERANA line?Eduardo Ojito: CIM, together with the Genetic Engineering and Biotechnology Center (CIGB), are Cuba's leading institutions when it comes to immunology and cancer technologies.We're the brain trust so to speak-of all the research centers under the BioCubaFarma umbrella, CIM and CIGB are the main repositories of knowledge about these technologies and immune response.Our institution has over 25 years' experience producing monoclonal antibodies (mAbs) and currently provides the national health system with several products using these proteins, including erythropoietinstimulating agents, granulocyte colony-stimulating factor and human growth hormone.Recognizing this expertise, the Finlay Vaccine Institute (IFV) approached us to produce the proteins used in our country's fi rst COVID-19 candidates, SOBERANA 01 and SOBERANA 02.
Referência(s)